Biomea Fusion, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael J. Hitchcock
- Full Time Employees
- 40
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1599 Industrial Road San Carlos CA United States of America 94063
- IPO Date
- Apr 16, 2021
- CIK
- 0001840439
- Website
- biomeafusion.com
- Similar Companies
- Business
- Biomea Fusion, Inc. (BMEA) is a clinical-stage biopharmaceutical company that develops oral covalent small-molecule inhibitors targeting genetically defined cancers and metabolic diseases, including diabetes and obesity, using its proprietary FUSION System discovery platform. The company offers a pipeline of novel candidates, including icovamenib (BMF-219), an oral menin inhibitor in Phase II trials for type 2 diabetes (T2D; COVALENT-111 with positive 52-week data and COVALENT-112 ongoing), type 1 diabetes (T1D), and previously in oncology indications such as acute myeloid leukemia and multiple myeloma; BMF-650, a next-generation oral GLP-1 receptor agonist in Phase I (GLP-131) for obesity with preclinical nonhuman primate data showing up to 15% weight loss; and earlier-stage assets like BMF-500 (FLT3 inhibitor). Founded in 2017 and headquartered in Redwood City, California, Biomea Fusion operates primarily in the United States with global preclinical and clinical activities focused on patients underserved by existing therapies. Recent developments include a strategic realignment to prioritize diabetes and obesity programs by discontinuing certain oncology efforts, a June 2025 public offering raising approximately $42.8 million to extend cash runway into second-half 2026, workforce and expense reductions targeting 40% quarterly cuts, Investigational New Drug submission and first-patient dosing for BMF-650 in 2025, planned Phase II initiations for icovamenib in severe insulin-deficient T2D (COVALENT-212) and GLP-1 inadequate responders (VALE-212) in Q4 2025, and an oral presentation on icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease in December 2025.
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
Biomea Fusion to Participate at Upcoming Investor Conferences
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinical Trial Insights Transcript
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type 1 Diabetes Transcript
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
Biomea Fusion, Inc. (BMEA) Discusses Menin Inhibition Mechanism and Therapeutic Potential in Diabetes Transcript
Biomea Fusion, Inc. (BMEA) Discusses Phase I Data and Clinical Potential of Oral GLP-1 Receptor Antagonist for Obesity Transcript
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
Biomea Fusion (BMEA) Expected to Announce Quarterly Earnings on Monday
Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
Biomea Fusion to Participate at Upcoming Investor Conferences
Biomea Fusion Spotlights Diabetes, Obesity Pipeline at JPMorgan Conference, Sets 2026 Milestones
Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript